Nicotinamide Mononucleotide (NMN): Difference between revisions

Nicotinamide Mononucleotide (NMN) (view source)

369 bytes added , 2 December 2023

2,851

edits

@@ Line 366: / Line 366: @@
 |
 |
+* 250 mg of NMN for 12 weeks does not significantly reduce artery stiffness — a risk factor for cardiovascular disease, dementia, and death — in healthy middle-aged adults.
+* However, NMN reduces artery stiffness in individuals with high blood-glucose and body mass index (weight/height).
+* Blood vessel biological aging is reversed by 2 years with NMN treatment.
 |-
 |{{pmid text|36443648}}